Biomedical subjects
D Blumenstock
Publications and source records attributed to D Blumenstock.
Genetic studies of bone marrow transplantation in the canine species.
Explore the source record for details and available documents.
Histocompatibility studies in a closely bred colony of dogs. V. Mechanisms of cellular adaptation in long-term DL-A identical radiation chimeras.
20 Cooperstown beagles of known DL-A genotypes (B" dogs) were exposed to supralethal total body irradiation and received a bone marrow allograft from a DL-A identical donor (A" dog); the resulting chimeras have survived uneventfully for 882, 1466 days, with no evidence of secondary disease, and have been tolerant to kidney and skin allografts obtained from the donor of marrow. Treatment of "A" dogs with serum obtained from their long-term "B" chimeras had no significant effect upon the ability of the recipients to reject "B" skin allografts...
Induction of tolerance to third-party donor organs in canine radiation chimeras.
Explore the source record for details and available documents.
Parameters of allogeneic unresponsiveness in canine radiation chimerae, with particular reference to the possible existence of three closely linked genetic systems relevant to bone marrow transplantation.
Explore the source record for details and available documents.
Histocompatibility studies in a closely bred colony of dogs.
17 Cooperstown beagles of known DL-A genotypes were exposed to supralethal total body irradiation and received a bone marrow allograft from a DL-A-identical donor; 11 littermate and 6 nonlittermate donor-recipient pairs were studied. The recipients are surviving uneventfully for 315, 364, 424, 440, 531, 531, 584, 605, 625, 635, and 649 days in the littermate group and for 211, 279, 280, 368, 479, and 480 days in the nonlittermate group. The radiation chimeras underwent bilateral nephrectomy and received a kidney allograft obtained from their respective marrow donor within 43-120 days after bone marrow transplantation. The renal allografts are surviving for 191, 200, 221, 234, 313, 349, 361, 377, 378, 405, 441, 444, 482, 557, 580, 581, and 586 days, respectively. 12 of 13 skin allografts obtained from the marrow donor are at present surviving in the recipients for 107, 110, 110, 110, 116, 122, 128, 143, 143, 162, 178, and 199 days, respectively; one graft was rejected at 84 days. In contrast, the radiation chimeras rejected 25 skin allografts obtained from DL-A-incompatible donors within 10.5-21 days (MST = 15.2 days). Skin transplants obtained from DL-A-identical siblings of the bone marrow donors were rejected within 20-36 days (MST = 25.8 days) in recipients of bone marrow cells obtained from littermate donors. Recipients of nonlittermate bone marrow transplants accorded such allografts a prolonged survival time of 27-76 days (MST = 56.2 days). Prospective selection of genotypically DL-A-identical donor-recipient pairs results in the regularly reproducible long-term survival of bone marrow allografts. The radiation chimeras produced in this manner have developed a donor-specific state of unresponsiveness to kidney and skin allografts. The results are consistent with the existence in the canine species of at least three closely linked genetic systems relevant to transplantation, including DL-A, MLC, and a possible bone marrow transplantation locus.
Immunologically specific allogeneic unresponsiveness in DL-A-identical radiation chimeras: a follow-up report.
Explore the source record for details and available documents.
Allotransplantation of the lung in beagle and mongrel dogs prospectively typed for lymphocytic antigens.
Explore the source record for details and available documents.
[Immunosuppressive therapy applied to allogenic lung transplants].
Explore the source record for details and available documents.
[Tolerance to the renal graft by combination, prior to transplantation, of immunosuppressive and antigenic treatments].
Explore the source record for details and available documents.
[Early results of pulmonary allotransplants in dogs treated with methotrexate and anti-lymphocyte serum].
Explore the source record for details and available documents.